enGene is a late-stage biotechnology company focused on advancing genetic medicines through innovative therapeutic delivery to mucosal tissues and other organs. The company is currently evaluating its lead program, EG-70, in a pivotal study for patients with non-muscle invasive bladder cancer who are unresponsive or naïve to Bacillus Calmette-Guérin treatment. Utilizing its proprietary Dually Derivatized Oligochitosan platform, enGene aims to enhance the penetration of mucosal tissues and deliver a variety of therapeutic cargo, including DNA and RNA. With a commitment to quality and compliance, enGene collaborates closely with external manufacturing partners to ensure the successful development and production of its gene therapy products.